Whereas ovarian cancer is the fifth leading cause of cancer deaths of women in the United States and causes more deaths than any other gynecologic cancer; Whereas in the United States, a woman’s lifetime risk of being diagnosed with ovarian cancer is about 1 in 78; Whereas the American Cancer Society estimates 19,710 cases of ovarian cancer will be newly diagnosed in 2023 and 13,940 individuals will die from the disease nationwide; Whereas the five-year survival rate for ovarian cancer is 46.5 percent and survival rates vary greatly depending on the stage of diagnosis; Whereas the five-year survival rate for ovarian cancer is over 90 percent for individuals diagnosed in early stages; Whereas while the mammogram can detect breast cancer and the Pap smear can detect cervical cancer, there is no reliable early detection test for ovarian cancer; Whereas, in June 2007, the first national consensus statement on ovarian cancer symptoms was developed to provide consistency in describing symptoms to make it easier for women to learn and remember those symptoms; Whereas Black women with ovarian cancer are more likely to have late-stage diagnoses, receive lower quality clinical services, and have lower 5-year survival rates than non-Black women; Whereas Black women have a 5-year ovarian cancer mortality rate of 62 percent, while the 5-year ovarian cancer mortality rate is 54 percent for White women; Whereas women of color, low-income women, and women living in rural areas have more barriers to accessing a standard quality of care and are more likely to receive care at a facility that has poorer adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines; Whereas the proportion of ovarian cancer cases in women serving on active duty who are less than 45 years of age is substantially greater than in the general population